ADC Therapeutics Reports Q3 2025 Financial Results with $16.4M Revenue and $41M Net Loss

ADC Therapeutics SA reported its financial results for the third quarter of 2025, revealing a total revenue of $16.4 million, a decrease of 11% from $18.5 million in the same period last year. The decline was primarily driven by a 12.6% drop in product revenues, which fell to $15.8 million from $18.0 million, attributed to lower sales volume despite a higher average selling price. License revenues and royalties, however, increased significantly to $0.7 million from $0.4 million, reflecting improved royalty income from strategic agreements.

In terms of operating expenses, ADC Therapeutics reported a total of $47.4 million for the quarter, down 12.3% from $54.0 million in the prior year. The reduction was largely due to decreased research and development costs, which fell by 17.5% to $26.8 million, as the company streamlined its focus on ZYNLONTA and discontinued certain preclinical programs. General and administrative expenses also decreased by 16.8% to $8.3 million, reflecting lower professional fees and employee-related costs. The company recorded a net loss of $41.0 million, a slight improvement from a loss of $44.0 million in the same quarter of 2024.

Significant strategic developments included the approval of a restructuring plan aimed at focusing resources on ZYNLONTA and advancing a new prostate-specific membrane antigen-targeting ADC. This restructuring involved shutting down the UK facility and reducing the workforce by approximately 30%. The company also completed a private placement in June 2025, raising $100 million, and another in October 2025, generating $60 million, to support its operational needs and product expansion.

Operationally, ADC Therapeutics continues to focus on its flagship product, ZYNLONTA, which has received various regulatory approvals in multiple regions. The company is actively pursuing clinical trials to expand the product's indications, including ongoing studies in combination therapies for diffuse large B-cell lymphoma. As of September 30, 2025, the company had cash and cash equivalents of $234.7 million, which it believes will be sufficient to fund operations for at least the next twelve months.

Looking ahead, ADC Therapeutics anticipates continued investment in its research and development efforts, particularly for ZYNLONTA and the new ADC program. The company is also exploring additional financing options and strategic collaborations to support its growth initiatives. However, it acknowledges the inherent risks and uncertainties in the biotechnology sector, including the need for ongoing capital to fund operations and the potential for delays in clinical trials and regulatory approvals.